Medicare Enrolled

Dr. Samuel Kuo, M.D.

Hematology & Oncology · Tulare, CA
Practice pattern: Clinical Cardiology — Primarily office-based clinical cardiology
Low-engagement
1088 N CHERRY ST, Tulare, CA 93274
5596888899
In practice since 2005 (20 years)
NPI: 1861478422 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kuo from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kuo? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Kuo

Dr. Samuel Kuo is a hematology & oncology specialist in Tulare, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Kuo performed 3,230 Medicare services across 479 unique beneficiaries.

Between the years covered by Open Payments, Dr. Kuo received a total of $4,010 from 37 pharmaceutical and/or device companies across 187 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Kuo is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 37% volume in CA $4,010 industry payments

Medicare Practice Summary

Medicare Utilization ↗
3,230
Medicare services
Top 37% in CA for hematology & oncology
479
Unique beneficiaries
$41
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~162 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Denosumab injection (Prolia/Xgeva) 1,860 $19 $26
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
752 $70 $110
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
407 $95 $150
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
95 $12 $30
Influenza vaccine, quadrivalent, 0.5 ml dosage 46 $20 $25
Flu vaccine administration
This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient.
46 $31 $35
New patient office visit, complex (60-74 min) 24 $170 $280
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$4,010
Total received (2018-2024)
Avg $668/year across 6 years
Top 47% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
37
Companies
187
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,837 (95.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$173 (4.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,110
2023
$889
2022
$1,288
2021
$494
2019
$208
2018
$21

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Janssen Biotech, Inc.
$262
Lilly USA, LLC
$158
SOBI, INC
$135
AstraZeneca Pharmaceuticals LP
$102
PFIZER INC.
$74
Merck Sharp & Dohme LLC
$67
ABBVIE INC.
$43
Azurity Pharmaceuticals, Inc.
$38
Celgene Corporation
$36
Regeneron Healthcare Solutions, Inc.
$28
Novartis Pharmaceuticals Corporation
$26
Daiichi Sankyo Inc.
$25
E.R. Squibb & Sons, L.L.C.
$23
TAIHO ONCOLOGY, INC.
$20
ADC Therapeutics America, Inc.
$20
Rigel Pharmaceuticals, Inc.
$20
Incyte Corporation
$18
SpringWorks Therapeutics, Inc.
$15
Top 3 companies account for 50.0% of 2024 payments
All-time payments by company (2018-2024) ›
Janssen Biotech, Inc.
$885
PFIZER INC.
$335
Lilly USA, LLC
$314
Novartis Pharmaceuticals Corporation
$227
Amgen Inc.
$211
Merck Sharp & Dohme LLC
$199
SOBI, INC
$189
Incyte Corporation
$183
AstraZeneca Pharmaceuticals LP
$169
Regeneron Healthcare Solutions, Inc.
$132
Kite Pharma, Inc.
$96
ABBVIE INC.
$92
Celgene Corporation
$92
Exelixis Inc.
$92
Sobi, Inc
$83
Mirati Therapeutics, Inc.
$82
Takeda Pharmaceuticals U.S.A., Inc.
$78
Merck Sharp & Dohme Corporation
$72
Daiichi Sankyo Inc.
$52
Bayer HealthCare Pharmaceuticals Inc.
$49
Eisai Inc.
$45
Gilead Sciences, Inc.
$41
Azurity Pharmaceuticals, Inc.
$38
BeiGene USA, Inc.
$24
Pharmacyclics LLC, An AbbVie Company
$23
E.R. Squibb & Sons, L.L.C.
$23
Ipsen Biopharmaceuticals, Inc
$22
TAIHO ONCOLOGY, INC.
$20
ADC Therapeutics America, Inc.
$20
Rigel Pharmaceuticals, Inc.
$20
Biohaven Pharmaceutical Holding Company Ltd.
$19
PharmaEssentia USA Corporation
$17
SpringWorks Therapeutics, Inc.
$15
Horizon Therapeutics plc
$14
Boehringer Ingelheim Pharmaceuticals, Inc.
$13
Cumberland Pharmaceuticals, Inc.
$13
GENZYME CORPORATION
$12
Top 3 companies account for 38.2% of all-time payments
Associated products mentioned in payments ›
BESREMI · BRUKINSA · CABOMETYX · CALQUENCE · CARVYKTI · CREON · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELIQUIS · ENHERTU · ERLEADA · GILOTRIF · IBRANCE · ICLUSIG · IMBRUVICA · INJECTAFER · INLYTA · JAKAFI · JANUVIA · KEYTRUDA · KISQALI · KRAZATI · KRYSTEXXA · Kerendia · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · MEKINIST · NURTEC ODT · Nplate · OGSIVEO · ONUREG · OPDUALAG · Onivyde · PROMACTA · Pomalyst · Prolia · REBLOZYL · Rezlidhia · SANCUSO · SCEMBLIX · Stivarga · TAGRISSO · TASIGNA · Trodelvy · UBRELVY · VENCLEXTA · VERZENIO · VIVIMUSTA · XALKORI · XTANDI
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (96%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a hematology & oncology specialist in Tulare?
Compare hematology & oncology specialists in the Tulare area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
3
Per 100K population
0.6
County median income
$69,489
Nearest hospital
ADVENTIST HEALTH TULARE
0.0 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Kuo is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Kuo experienced with denosumab injection (prolia/xgeva)?
Based on Medicare claims data, Dr. Kuo performed 1,860 denosumab injection (prolia/xgeva) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kuo receive payments from pharmaceutical companies?
Yes. Dr. Kuo received a total of $4,010 from 37 companies across 187 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kuo's costs compare to other hematology & oncology specialists in Tulare?
Dr. Kuo's average Medicare payment per service is $41. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kuo) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →